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ABSTRACT
Introduction: This study aimed to determine if
data mining methodologies could identify
reproducible predictors of dapagliflozin-specific
treatment response in the phase 3 clinical
program dataset.
Methods: Baseline and early treatment
response variables were selected and data
mining used to identify/rank all variables
associated with reduction in glycated
hemoglobin (HbA1c) at week 26. Generalized
linear modeling was then employed using an
independent dataset to identify which (if any)
variables were predictive of dapagliflozin-
specific treatment response as compared with
treatment response in the study’s control arm.
The most parsimonious (i.e., simplest) model
was validated by meta-analysis of nine other
trials. This staged approach was used to
minimize risk of type I errors.
Results: From the large dataset, 22 variables
were selected for model generation as
potentially predictive for dapagliflozin-specific
reduction in HbA1c. Although baseline HbA1c
was the variable most strongly associated with
reduction in HbA1c at study end (i.e., the best
prognostic variable), baseline fasting plasma
glucose (FPG) was the only predictive
dapagliflozin-specific variable in the model.
Placebo-adjusted treatment effect of
dapagliflozin plus metformin vs. metformin
alone for change in HbA1c from baseline was
-0.65% at the average baseline FPG of
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192.3 mg/dL (10.7 mmol/L). This response
changed by -0.32% for every SD [57.2 mg/dL
(3.2 mmol/L)] increase in baseline FPG. Effect of
baseline FPG was confirmed in the meta-analysis
ofninestudies,but themagnitudewas smaller.No
other variable was independently predictive of a
dapagliflozin-specific reduction in HbA1c.
Conclusions: This methodology successfully
identified a reproducible baseline predictor of
differential response to dapagliflozin. Although
baseline FPG was shown to be a predictor, the
effect size was not of sufficient magnitude to
suggest clinical usefulness in identifying
patients who would uniquely benefit from
dapagliflozin treatment. The findings do
support potential benefit for dapagliflozin
treatment that is consistent with current
recommended use.
Keywords: Dapagliflozin; Data mining; Fasting
plasma glucose; Machine learning; Meta-
analysis; Predictor; Prognostic factors;
Response profiling; Type 2 diabetes mellitus
INTRODUCTION
Choosing among the many antihyperglycemic
treatment options now available for patients
with type 2 diabetes mellitus (T2DM) involves
matching the clinical profile of each drug,
which has been assessed using aggregate data
in clinical trials, to the characteristics of the
individual patient [1]. In practice, the relevant
parameters involve tolerability and safety; for
example, whether the treatment exposes the
patient to hypoglycemia or if the patient has
renal impairment. Relatively little is known
about the differential efficacy of a drug on a
patient-by-patient basis, and the factors that
might underlie differential responses are not
well understood [2, 3].
Dapagliflozin, a sodium-glucose co-
transporter 2 inhibitor (SGLT2) approved for
use in the EU, US, and numerous other
countries, has been shown to reduce
hyperglycemia consistently by increasing
urinary glucose excretion [4]. Additionally,
dapagliflozin has been associated with
reductions in body weight and blood pressure,
and an incidence of adverse events comparable
with those seen in control arms in a diverse
patient population from an extensive clinical
trial program [5–10]. The dapagliflozin
development program, which included a large
number of patients from independent clinical
trials, provided the opportunity to explore the
possibility that baseline characteristics or early
treatment responses might predict which
patients would most benefit from dapagliflozin
therapy.
We used data mining—a computational
process used to identify patterns in complex
datasets—to extract clinically useful
information from dapagliflozin phase 3 trials
that might otherwise have remained unknown.
Data mining algorithms are used to interrogate
data to develop a classification rule that can be
predictive for outcomes of interest [11]. They
feature extensively in handling very large
datasets, where such a hypothesis-independent
approach has delivered particularly innovative
insights. To date, there are limited examples of
the use of such applications to identify
predictive variables within conventional
clinical datasets, as generated during late-stage
clinical trials [12]. A comprehensive analysis of
the dapagliflozin phase 3 program was
undertaken to determine whether there are
baseline characteristics or early responses to
treatment that could be used to predict which
patients would benefit the most from receiving
dapagliflozin treatment in conjunction with
other treatments administered in the program.
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METHODS
The overall analysis comprised three stages: (1)
variable selection, (2) model generation, and (3)
clinical validation (Fig. 1). Each stage used data
from independent clinical trials within the phase
3 program. Studies were selected for analysis if
they had a dapagliflozin arm and had been
completed by the time this analysis was
initiated; all studies fulfilling these criteria were
used in these analyses (Table 1) [5, 9, 13–19].
The study was designed with expert clinical,
personalized healthcare, statistical, and
informatics input. All analysis methods and
variable selection criteria were agreed a priori
and were captured inanexploratoryanalysis plan.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
VARIABLE SELECTION
The variable selection stage was performed on
data from the metformin plus dapagliflozin arm
of a randomized, 52-week, double-blind, active-
controlled non-inferiority study of dapagliflozin
vs. glipizide as add-on to metformin therapy in
patients with T2DM with inadequate glycemic
control on metformin alone [8]. The primary
endpoint of this study was change in glycated
hemoglobin (HbA1c) from baseline to week 26.
In the studies used in the later stages, the
primary endpoint was measured at week 24
instead of week 26. Missing 26-week data were
imputed using the last observation carried
forward technique. Similarly, the early post-
treatment time point was week 3, but because
studies used in subsequent stages of the analysis
collected data at week 4, week 4 data were used
in both the model generation and validation
stages. The goal at this stage was to identify
those baseline and early treatment response
variables with the largest influence on change
in HbA1c level. These variables were then ranked
based on the strength of their association with
the endpoint. Due to a lack of a control arm
(metformin alone) in this specific dataset, it was
not possible to assess which variables would be
specific predictors of dapagliflozin treatment
response per se as opposed to more general
prognostic factors. The term prognostic as used
here has virtually the same meaning as in
routine clinical medicine; namely, baseline or
early response characteristics that influence
Fig. 1 Basic plan of the analysis: a staged approach. HbA1c glycated hemoglobin
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Table 1 Dapagliﬂozin studies used in the analyses
























5 mg ? metformin XR,




10 mg ? metformin XR,









Men, women 18–77 years,
HbA1c 7.5–12%, treatment








Dapagliﬂozin 2.5, 5, or
10 mg vs. placebo
399; dapagliﬂozin 5 or
10 mg (N = 265)
Men, women 18–77 years,
HbA1c 7–10%, inadequately
controlled with metformin,





Dapagliﬂozin 1, 2.5 or 5 mg
vs. placebo
334; dapagliﬂozin 5 or
10 mg (N = 262)
Men, women 18–77 years,
HbA1c C7 to B10%,
treatment naı¨ve, exclusion






Dapagliﬂozin 10 mg vs.
placebo
179; dapagliﬂozin
10 mg (N = 88)
Men, women 30–75 years,
HbA1c 6.5–8.5%, inadequately
controlled with metformin,




Dapagliﬂozin 10 mg vs.
placebo added to usual care
899; dapagliﬂozin
10 mg (N = 448)
Men, women C45 years,
HbA1c C7 to B10%,
previously treated,
documented CVD
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outcome, independent of treatment. In
contrast, a predictor is a baseline or early
response characteristic that has an impact on
response to a particular treatment.
The variables selected for model generation
were determined by combining the variable lists
from two different data mining methods,
gradient boosting [20, 21] and elastic net [22],
using a set of data-driven guidelines. These two
methods were selected to complement each
other. (For elastic net, the most influential
variables were identified as the variables
selected when the regularization parameter
lambda was increased to the highest level
achieving a cross-validated mean squared error
(CV MSE) within 1 standard error of the lowest
CV MSE, and for gradient boosting it was the
top ranked variables with the cutoff determined
by a noticeable drop in relative influence score).
Two variable lists were defined: clinically
relevant data available at baseline, and
clinically relevant data available at baseline
Table 1 continued












10 mg (N = 223)
Men, women mean age





Dapagliﬂozin 10 mg vs.
placebo added to usual care
945; dapagliﬂozin
10 mg (N = 474)
Men, women mean age








10 mg ? pioglitazone
418; dapagliﬂozin 5 or
10 mg (N = 280)
Men, women C18 years,
HbA1c C7 to B11%, either
treatment naı¨ve or previously






Dapagliﬂozin 2.5, 5 or 10 mg
vs. placebo ? open-label
glimepiride
435; dapagliﬂozin 5 or
10 mg (N = 292)
Men, women C18 years,








Dapagliﬂozin 2.5, 5 or 10 mg
vs. placebo ? open-label
existing insulin ± B2 oral
hypoglycemic drugs
568; dapagliﬂozin 5 or
10 mg (N = 389)
Men, women 18–80 years,
HbA1c C7.5 to B10.5%,
inadequately controlled with
insulin ± oral hypoglycemic
drugs 47.4–52.1% had
previous CVD (hypertension)
CVD cardiovascular disease, HbA1c glycated hemoglobin, NYHA New York Heart Association; XR extended release
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plus data available at the early post-treatment
time point.
MODEL GENERATION
The purpose of model building was to refine the
selected variables by eliminating prognostic
variables (i.e., those that are associated with
response independent of treatment) and false
positives (i.e., those that were positive in the
variable selection phase only) to build a model
predictive of dapagliflozin-specific HbA1c
reduction at 24 weeks. The lists of variables
identified in the variable selection stage
(Table 2) were used for model generation in an
independent dataset. During this stage, the
purpose was to build a robust predictive model
that would include variables with estimated
effect sizes large enough to be clinically
meaningful. Model generation was carried out
in a placebo-controlled dataset, allowing
variables predictive of response to
dapagliflozin treatment specifically to be
distinguished from those variables that were
predictive of response to any treatment.
The dataset comprised two randomized,
24-week, double-blind, active-controlled
studies comparing the combinations of
dapagliflozin (5 or 10 mg) plus metformin
with dapagliflozin plus placebo or metformin
plus placebo [10]. The modeling comprised
further variable selection, model refinement,
and assessment of model performance for
patient segmentation. Both univariate and
multivariate stepwise linear regression
techniques were used to model the main
effects of treatment, each clinical variable, and
each treatment by clinical variable interaction
term. The SAS (SAS institute, SAS Foundation
v9. 2, Cary NC, USA) software package was used
for these analyses.
The most parsimonious model (i.e., the
simplest model which best described the
predictive relationship with dapagliflozin









HOMA2 beta cell functiona
Creatinine





Glomerular ﬁltration rate, calculated (MDRD
equation)
B. Baseline 1 week 3 change from baseline (LOCF)
Change from baseline in hemoglobin A1C (LOCF)
Change from baseline in sitting heart rate (LOCF)
Change from baseline in fasting plasma glucose (LOCF)
Change from baseline in weight (LOCF)
Baseline weight
Baseline sitting heart rate
Baseline CRP, high sensitivity fastinga
Baseline fatty acids, fasting free
CRP C-reactive protein, HOMA Homeostasis model
assessment, LDL low-density lipoprotein, LOCF Last
observation carried forward, MDRD Modiﬁcation of diet
in renal disease, T2DM type 2 diabetes mellitus
a Not available in the studies used for the model-building
phase
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treatment response) was put forward for
validation.
CLINICAL VALIDATION
The selected model was validated using a
meta-analysis of nine phase 3 placebo-
controlled trials in patients receiving various
treatments, such as insulin, glimepiride,
pioglitazone, metformin, or sitagliptin
(Table 1). Because we were trying to identify
predictors of dapagliflozin response that
would be valid for virtually any patient with
T2DM, it was important to include trials that
were heterogeneous with respect to
concomitant treatments as well as to the
demographic and disease characteristics of
the trial participants. The primary aim was
to use a robust method to estimate the
predictive effect of fasting plasma glucose
(FPG) in the remaining individual studies,
from which we derived an overall estimate
using a meta-analytic approach.
The meta-analysis was conducted using
Bayesian hierarchical modeling, which
accounts for any heterogeneity between trials
by adaptively fitting the data from different
trials based on their similarity. This
methodology allows inferences to be drawn at
the level of individual trials and for the entire
set of trials [23].
RESULTS
Variable Selection Phase
Data from 400 patients with a value for their
change in HbA1c at week 26, including 46
variables of clinical relevance at baseline, were
used in the variable selection stage. An
additional 11 explanatory variables
representing change at week 3 from baseline
were used in the baseline plus early follow-up
dataset. Variables included patient
demographics, baseline lipids, kidney
function, HbA1c, FPG, and insulin resistance
and sensitivity. A total of 14 baseline variables
and 8 additional baseline plus week 3 variables
were selected for model generation based on the
strength of their association with reduction in
HbA1c at week 26 (Table 2). Of these, only 17
variables were carried forward to the model
generation phase because 5 of the variables
chosen were not included in the dataset of the 2
studies used for model generation. Prominent
among the baseline variables put forward for
validation were HbA1c and FPG, and among the
early response variables were change from
baseline to week 3 in HbA1c and in FPG.
Model Generation Phase
Modeling identified two variables that could
have independent predictive value. For change
from baseline in HbA1c at week 24, baseline FPG
and race were found to significantly influence
the effect of dapagliflozin treatment in the two
studies. Other baseline and early post-treatment
time point variables were either found to be
covariates, rather than predictors of
dapagliflozin-specific treatment response (e.g.,
HbA1c), or did not replicate in the independent
dataset and were probably false positives (e.g.,
urinary glucose concentration).
A linear relationship between baseline FPG
and outcome was modeled, which suggested
that the placebo-adjusted response to
dapagliflozin treatment was greater in patients
with high FPG at baseline compared with those
with lower levels. This effect remained after
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adjustment for a number of prognostic
covariates (main effects) including baseline
HbA1c, which was the strongest prognostic
factor. Further analysis of patients in the
highest tertile of baseline FPG [C220 mg/dL
(12.2 mmol/L)] indicated that there was no
difference in demographics or adverse event
profile in these patients compared with patients
with lower baseline FPG, for whom the model
predicts lower efficacy.
An independent predictive effect of race was
identified, which suggested that African
American patients may benefit more from
dapagliflozin treatment than white and Asian
patients. No other predictive effect of race was
found. However, the subgroup of African
American patients (with an HbA1c
measurement on treatment) was small (n = 29,
4%), resulting in imprecise estimates of
treatment response. This limitation precluded
consideration of race as a predictive variable
and it was not advanced to the validation phase
of the analysis. Moreover, the number of
African Americans in the nine studies included
in the meta-analysis was too small (ranging
from 2.1 to 5.9% of the study populations) to be
able to validate a proposed model.
The linear model, limited to the single
variable FPG, was used to predict the effect of
metformin plus dapagliflozin compared with
metformin alone for all white (n = 628, 81%)
and Asian patients (n = 119, 15%) in the study
with HbA1c measurement on treatment. The
placebo-adjusted treatment effect (i.e., change
in HbA1c from baseline to week 24 of
dapagliflozin plus metformin vs. metformin
alone) in this model was estimated to be
–0.65% (95% CI -0.84 to –0.47), with average
baseline FPG of 192.3 mg/dL (10.7 mmol/L)
(Fig. 2). The predicted placebo-adjusted HbA1c
response varied according to the level of
baseline FPG, from a treatment benefit of
–0.25% (95% CI –0.55 to –0.05) for 120 mg/dL
(6.7 mmol/L) baseline FPG to –1.36% (95% CI
–1.82 to –0.90) for 320 mg/dL (17.8 mmol/L)
baseline FPG (Fig. 2). These estimates of the
effect sizes of dapagliflozin treatment based on
baseline FPG were not affected by the omission
of the prognostic factors from the model.
Clinical Validation Phase
A meta-analysis technique used to assess the
interaction between baseline FPG and
treatment in nine dapagliflozin studies
(Table 1) indicated that patients with higher
levels of baseline FPG were repeatedly found to
have a greater response to dapagliflozin
treatment, on average, compared with patients
with lower baseline FPG levels. The observed
effects were consistent with the initial
hypothesis derived from the first two stages of
the project, but the overall estimate from the
Bayesian hierarchical model was smaller and
was not statistically significant (a median
Fig. 2 Model of fasting plasma glucose (FPG) as predictor
(In White and Asian patients n = 747). bDapagliﬂozin
treatment effect increases by 32% for every one unit
standard deviation [57.2 mg/dL (3.2 mmol/L)] increase in
baseline FPG; dotted lines represent the 95% conﬁdence
interval. HbA1c glycated hemoglobin
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additional effect of dapagliflozin of -0.12%
change in HbA1c at 24 weeks for every
additional 50 mg/dL of baseline FPG; 95%
credible interval crossed 0, Fig. 3). In addition,
there was variability in the effect size estimates
across the nine different studies (Fig. 3) that led
to wide confidence limits around the overall
estimate derived from the meta-analysis.
DISCUSSION
A comprehensive analysis of the dapagliflozin
phase 3 program was undertaken with the goal
of identifying and validating baseline
characteristics (or early responses to treatment)
that could be used to predict which patients
would respond best to dapagliflozin treatment.
We used a novel, customized approach of
response profiling to identify predictors of
dapagliflozin efficacy of clinical value in the
treatment of patients with T2DM. From an
initial group of 48 variables, of which 28 were
selected for modeling, only one variable, FPG,
was found to significantly predict response to
dapagliflozin. Although the results of the meta-
analysis indicate that baseline FPG was
reproducibly predictive of the effect of
dapagliflozin on HbA1c change from baseline
to 24 weeks, the magnitude and wide
confidence interval of the effect size observed
was neither clinically nor statistically
significant, giving little potential scope for use
as a clinical predictor of efficacy. Baseline
HbA1c, which was found to be the strongest
prognostic variable in our analyses (i.e.,
associated independently of treatment with
the largest change in HbA1c from baseline to
week 24/26), was not an independent predictor
of dapagliflozin-specific treatment effect.
Our results support the findings of
conventional, hypothesis-driven analyses,
which have shown that dapagliflozin offers
significant clinical benefit across all groups of
patients in a broad-based clinical trial program,
including patients across the continuum of
T2DM, from treatment naı¨ve to those
requiring high doses of insulin [24, 25]. It is
also consistent with previously published
evidence showing that the beneficial effect of
dapagliflozin therapy in terms of reduction
from baseline in HbA1c is greatest in those
with the highest baseline HbA1c [6]. The
methodology applied was sufficiently sensitive
to detect a signal of a predictive marker for
differential response to dapagliflozin that was
below a threshold of clinical significance,
suggesting that the model would have been
able to detect a clinically relevant predictor if
one were included in the original set of
variables evaluated in this analysis. Given the
breadth of the clinically available data captured
in the clinical trials databases and the
thoroughness of this analysis, however, it is
unlikely that we would have failed to include a
Fig. 3 Effect of baseline FPG on change in HbA1c from
baseline to week 24. cThese studies are shown for reference
only and were not included in the overall analysis. CVD
cardiovascular disease, DPP4 dipeptidyl peptidase-4, FPG
fasting plasma glucose, HbA1c glycated hemoglobin, Met
metformin, SU sulfonylurea, T2DM type 2 diabetes
mellitus, TZD thiazolidinediones
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potentially relevant clinically available variable
in this large set of variables. Our preliminary
conclusion, therefore, is that there are no
subgroups identifiable from baseline or from
baseline plus early on-treatment data in
dapagliflozin studies that are associated with
clinically relevant differential response to
dapagliflozin treatment.
We attempted to combine complementary
statistical methods for data mining to cast a
wide net for potential signals. Elastic nets [22]
allow an efficient handling of correlated
variables, while decision tree algorithms, such
as gradient boosting [20, 21], are most suitable
for the analysis of complex interactions and
heterogeneity. Combined, these two methods
complement each other and give a good chance
of finding predictive variables. Such an
approach, which poses a risk of type I error,
was controlled for by using a staged approach
(i.e., hypothesis generation, testing, and
validation) and multiple independent datasets.
The study described by Maeda et al. [12]
evaluating whether baseline HbA1c, post-
prandial glucose, body mass index, and
duration of diabetes may be predictors of
HbA1c reduction when using sitagliptin in
Japanese patients with T2DM, for example,
was less informative. This was because it only
involved one stage and could not distinguish
between prognostic and predictive effects
specific to sitagliptin, as no control arm was
included. In addition, control over type I error
was limited and there was no indication of
clinical relevance [12].
The strengths of the approach described
herein are its hypothesis-independent basis
and consequent ability to generate truly
innovative insights. This approach was
deliberately chosen to allow all studies to be
analyzed together and to identify any variables
that would be predictive of response across
studies and across the entire spectrum of
patients with T2DM. Because the full range of
baseline and early on-treatment data were
considered as variables that could potentially
affect treatment response, the analysis was not
limited to those that have a plausible rationale;
therefore, the potential to discover a completely
novel predictor was increased.
The weaknesses of the method are predicated
on the same basis and are exemplified by the
high false discovery rates requiring independent
validation to deliver sufficient confidence. One
way of partially overcoming this problem would
be to use a dapagliflozin add-on study that has a
placebo-control group for the variable selection
phase, which would facilitate identification of
possible dapagliflozin-specific effects and reduce
the false discovery rate. A second limitation is a
consequence of the fact that our approach
necessitated the measurement of factors across
the complete program of studies. Because the
studies that comprised the phase 3 clinical
development program for dapagliflozin were
relatively heterogeneous by design, the results
of meta-analysis of nine of the 12 studies is not
meaningful in its own right and should
therefore be interpreted with caution. In fact,
as shown in Fig. 3, the estimated effect size of
FPG as a predictor was quite large
(approximately 1 standard deviation) in
treatment-naı¨ve patients in the monotherapy
study [26], whereas it was estimated to be
essentially nil in the two studies of older
patients with cardiovascular disease [15, 17].
Although pooling of studies that were all similar
in design would have mitigated the problems
associated with study heterogeneity, the
realities of clinical development programs
make this an unavoidable limitation of dealing
with these data sets.
In conclusion, our findings are consistent
with those of conventional, hypothesis-driven
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analyses that dapagliflozin offers significant and
predictable clinical benefit across all groups of
patients, from treatment naı¨ve to those
requiring high doses of insulin [24, 25].
Furthermore, we suggest that this hypothesis-
independent approach may be applied to other
drugs for which substantial clinical data are
available.
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